Testosterone is almost universally framed as a male hormone. But women produce testosterone too — and it plays a critical role in sexual desire, energy, mood, cognitive function, and muscle tone. When levels drop, the effects can be profound and life-altering, yet low testosterone in women is dramatically underdiagnosed and undertreated.

If you've experienced a loss of sexual interest that doesn't fully explain itself — not stress, not relationship issues, not depression — low testosterone may be a central piece of the puzzle. Here's what the research shows, what the symptoms really look like, and what evidence-based treatment options are available.

Women and Testosterone: The Basics Most Doctors Skip

Women produce testosterone in two primary locations: the ovaries and the adrenal glands. A smaller amount is also produced peripherally through the conversion of other hormones in fat and skin tissue. In premenopausal women, total testosterone typically ranges from 15 to 70 ng/dL — far lower than male levels (300–1,000 ng/dL), but physiologically significant.

Testosterone in women performs several distinct functions:

  • Sexual desire (libido): Testosterone directly acts on androgen receptors in the brain, particularly in areas governing motivation and reward, to drive sexual interest
  • Arousal and sensation: Androgen receptors exist in the clitoris and vaginal tissue; testosterone supports sensitivity and tissue health
  • Energy and vitality: Testosterone supports mitochondrial function and overall metabolic energy
  • Mood and cognition: Low testosterone correlates with depressive symptoms, irritability, and brain fog independent of estrogen status
  • Muscle maintenance: Testosterone supports lean mass; low levels contribute to weakness and exercise intolerance
  • Bone density: Works alongside estrogen to maintain skeletal integrity

When Does Testosterone Decline in Women?

Female testosterone follows a predictable decline across the lifespan:

  • Peak levels: Ages 20–30
  • Age 40: Testosterone levels are roughly half of peak values in most women
  • Perimenopause: Testosterone fluctuates alongside estrogen and progesterone; some women experience sharp drops
  • Surgical menopause (oophorectomy): Removal of the ovaries causes an immediate 50% drop in testosterone — often the most dramatic and symptomatic decline
  • Natural menopause: Testosterone continues to decline, though more gradually than estrogen

Other causes of low testosterone in women include:

  • Oral contraceptive pills (increase SHBG, which binds testosterone and reduces free levels)
  • Adrenal insufficiency or dysfunction
  • Hypopituitarism
  • Chronic stress and elevated cortisol (suppresses androgen production)
  • Hypothyroidism (affects overall hormone metabolism)
  • Eating disorders or severe caloric restriction
  • Certain antidepressants (SSRIs can reduce libido via multiple mechanisms)

Symptoms of Low Testosterone in Women

The symptom profile of low T in women is often attributed to other causes — aging, stress, depression, or relationship issues. This leads to years of undertreatment. The core symptoms include:

Sexual Symptoms

  • Decreased or absent sexual desire (often the primary complaint)
  • Reduced arousal and diminished response to sexual stimulation
  • Difficulty achieving orgasm or reduced orgasm intensity
  • Decreased sensitivity in the clitoris and vaginal tissue
  • Reduced sexual thoughts and fantasies

Psychological and Cognitive Symptoms

  • Persistent fatigue not explained by sleep quality
  • Brain fog, poor concentration, memory lapses
  • Low mood or mild depression
  • Reduced motivation and sense of wellbeing
  • Irritability and emotional blunting

Physical Symptoms

  • Loss of muscle tone despite exercise
  • Increased body fat, particularly abdominal
  • Reduced exercise tolerance and recovery
  • Thinning pubic and axillary hair
  • Dry skin

Hypoactive Sexual Desire Disorder (HSDD): The Clinical Diagnosis

When low libido becomes distressing and persistent, it may meet the criteria for Hypoactive Sexual Desire Disorder (HSDD) — the most common female sexual dysfunction, affecting an estimated 10% of premenopausal women and up to 28% of postmenopausal women.

HSDD is defined by the DSM-5 (combined with female sexual arousal disorder as Female Sexual Interest/Arousal Disorder, or FSIAD) as persistently deficient or absent sexual thoughts, fantasies, and desire that causes significant distress. Notably, the diagnosis requires that the low desire causes the woman personal distress — not simply that she has lower desire than a partner.

Low testosterone is not the only cause of HSDD, but it is a significant and treatable contributor, particularly in women with surgical menopause, natural menopause, or documented low androgen levels. A comprehensive evaluation should assess testosterone alongside other hormones (estradiol, FSH, prolactin, thyroid), psychological factors, relationship dynamics, and medications.

What the Research Says About Testosterone Therapy in Women

The evidence for testosterone therapy in women with low libido and documented low testosterone is substantial — and stronger than many physicians realize.

The ISSWSH Guidelines

In 2019, the International Society for the Study of Women's Sexual Health (ISSWSH) published a process-of-care consensus statement concluding that testosterone therapy is appropriate for postmenopausal women with HSDD who have low or low-normal testosterone levels. The guidelines recommend:

  • Evaluation of testosterone levels before starting therapy
  • Use of physiologic doses targeting premenopausal reference ranges
  • Monitoring total and free testosterone levels every 6 months
  • Assessing benefit at 3–6 months and discontinuing if no improvement

Key Clinical Trials

A landmark systematic review and meta-analysis published in The Lancet Diabetes & Endocrinology (2019) analyzed 36 randomized controlled trials involving over 8,000 women. Key findings:

  • Testosterone therapy significantly improved sexual function, desire, arousal, orgasm, and pleasure
  • Improvements were seen across premenopausal, perimenopausal, and postmenopausal women
  • Short-term safety was acceptable; acne and hair growth were the most common side effects at physiologic doses
  • No significant increase in cardiovascular events, breast cancer, or mood disorders at recommended doses

The APHRODITE trial (Davis et al., NEJM, 2008) found that a 300 mcg/day testosterone patch significantly increased satisfying sexual events versus placebo in surgically menopausal women not on estrogen — one of the strongest randomized controlled trials in this area.

Research Finding: A 2019 Lancet meta-analysis of 8,000+ women found testosterone therapy significantly improved sexual desire, arousal, orgasm, and pleasure — with acceptable safety at physiologic doses.

FDA Status and Off-Label Use

Here's where the landscape gets complicated: there is no FDA-approved testosterone product for women in the United States. The FDA reviewed testosterone patches for women (Intrinsa) in 2004 and declined approval despite clinical efficacy, citing concerns about long-term cardiovascular and breast cancer safety data — a decision many experts consider excessively cautious given the evidence available.

In practice, testosterone therapy for women is widely used off-label in the U.S. using:

  • Compounded testosterone cream or gel: Custom formulated to female physiologic doses (typically 0.5–2% testosterone; 1–10 mg/day). Applied to the inner thigh, abdomen, or labia. Most commonly prescribed form.
  • Male testosterone gel (off-label, low dose): Products like AndroGel used at a fraction of male doses. Less precise for female dosing.
  • Testosterone pellets: Subcutaneous implants lasting 3–6 months; less adjustable but convenient for some patients.
  • Compounded injectable: Less common for women due to the precision challenges of very low dosing.

Compounded testosterone allows pharmacies to formulate bioidentical testosterone at doses appropriate for female physiology — something commercially available male products can't easily provide. Compounding pharmacies accredited by PCAB (Pharmacy Compounding Accreditation Board) are the recommended source for quality assurance.

How Testing Works

Evaluating testosterone in women requires understanding the right tests and their limitations:

  • Total testosterone: Most widely ordered; the starting point for evaluation. Normal female range: 15–70 ng/dL (varies by lab and assay)
  • Free testosterone: Biologically active portion not bound to SHBG or albumin. More clinically meaningful but more technically challenging to measure accurately
  • SHBG (Sex Hormone Binding Globulin): High SHBG (common with oral contraceptives, thyroid issues, liver disease) reduces free testosterone even when total testosterone is normal
  • DHEA-S: Adrenal androgen precursor; reflects adrenal contribution to androgen pool

Important caveat: many women with low-normal testosterone and significant symptoms benefit from treatment. There is no universally agreed "cutoff" below which treatment is indicated — clinical judgment incorporating symptoms, distress level, and lab values together guides the decision.

For testing via telehealth, a standard blood panel is ordered and drawn at a local LabCorp or Quest location. Results are reviewed with your provider during a follow-up visit, typically within a week of testing.

What to Expect from Treatment

When treatment is appropriate and correctly dosed:

  • Timeline: Most women notice improvements in libido and energy within 4–8 weeks; full effects can take 3–4 months
  • Dosing: Start low, titrate based on symptoms and follow-up lab values
  • Monitoring: Testosterone levels checked at 6–8 weeks initially, then every 6 months once stable
  • Side effects at physiologic doses: Mild acne (manageable), slight increase in facial hair possible; both resolve with dose reduction if needed
  • Virilization risk: Extremely low at appropriate female doses; occurs primarily with supraphysiologic dosing

Lifestyle Factors That Support Testosterone in Women

While therapy may be necessary for clinically low levels, these evidence-based lifestyle factors support healthy androgen levels:

  • Resistance training: Consistently shown to increase testosterone and DHEA in women; aim for 3–4 sessions per week
  • Adequate dietary fat: Cholesterol is the precursor to all steroid hormones; very low-fat diets impair androgen production
  • Zinc-rich foods: Zinc supports testosterone synthesis; found in beef, pumpkin seeds, legumes
  • Stress management: Chronic cortisol elevation suppresses androgen production via the HPA axis
  • Optimize sleep: The majority of testosterone production occurs during sleep; chronic sleep deprivation measurably lowers levels
  • Vitamin D: Functions as a steroid hormone; deficiency correlates with lower androgen levels in women
  • Avoid excessive alcohol: Alcohol increases SHBG and liver metabolism of testosterone

When to Seek Evaluation

Consider evaluation for low testosterone if you experience:

  • Persistent low or absent sexual desire lasting more than 6 months that causes personal distress
  • Fatigue and low energy not explained by sleep, thyroid issues, or depression
  • Cognitive changes (brain fog, concentration difficulty) without clear alternative explanation
  • Low mood unresponsive to lifestyle changes
  • Recent oophorectomy or early menopause
  • Long-term oral contraceptive use with new onset libido decline

Through telehealth, the evaluation process is straightforward: an intake questionnaire, a hormone panel blood draw, and a provider consultation to review results and discuss options — all without requiring an in-person visit.

The Bottom Line

Low testosterone in women is real, measurable, clinically significant, and treatable. The evidence from multiple large-scale trials supports testosterone therapy for women with documented low levels and sexual dysfunction — particularly HSDD. The absence of an FDA-approved women's product is a regulatory artifact, not a reflection of the underlying evidence.

If you've been told your hormones are "normal" but you still feel like yourself disappeared, it may be time for a more complete evaluation — one that includes a thoughtful assessment of your androgen levels alongside everything else.